Time filter

Source Type

Aboussekhra A.,King Faisal Specialist Hospital And Research Center
International Journal of Developmental Biology | Year: 2011

Since Paget's "Seed and Soil" hypothesis in 1889 on cancer growth and metastasis, several studies on various solid tumors have confirmed the active role of the tumor milieu on the onset, growth and spread of neoplastic cells. Fibroblasts constitute the major components of the tumor microenvironment (stroma), and are therefore the most studied cell type. Therefore, a large amount of data has emerged showing the cancer-promoting function of these cells through paracrine effects that escort tumor cells through all the carcinogenesis steps. This involves many signaling proteins that transmit the message in both directions, allowing cooperative crosstalk between cancer cells and their stroma. This prompted several researchers to investigate the potential use of the molecular and cellular features of active stromal fibroblasts to generate specific tools for prevention, prognosis and treatment of cancer. Herein, I review the cellular and molecular features of active cancer-associated fibroblasts and their origin. Additionally, I summarize our current understanding of the procarcinogenic actions of these cells and their potential prognostic value for breast cancer patients. © 2011 UBC Press.


Alkuraya F.S.,King Faisal Specialist Hospital And Research Center | Alkuraya F.S.,Alfaisal University
Trends in Genetics | Year: 2015

Although numerous approaches have been pursued to understand the function of human genes, Mendelian genetics has by far provided the most compelling and medically actionable dataset. Biallelic loss-of-function (LOF) mutations are observed in the majority of autosomal recessive Mendelian disorders, representing natural human knockouts and offering a unique opportunity to study the physiological and developmental context of these genes. The restriction of such context to 'disease' states is artificial, however, and the recent ability to survey entire human genomes for biallelic LOF mutations has revealed a surprising landscape of knockout events in 'healthy' individuals, sparking interest in their role in phenotypic diversity beyond disease causation. As I discuss in this review, the potentially wide implications of human knockout research warrant increased investment and multidisciplinary collaborations to overcome existing challenges and reap its benefits. © 2014 Elsevier Ltd.


Patent
King Faisal Specialist Hospital And Research Center | Date: 2014-07-18

The invention relates to a surgical apparatus, in particular a navigation probe for localizing and treating lesions in a brain, comprising: a body member (10) having an anterior end (20), a posterior end (30) and at least one groove (60, 62) extending for a particular length in a longitudinal direction of the body member (10) between said anterior end (20) and said posterior end (30); a saddle (70) adapted to securely hold a medical device, the saddle (70) being placed on said body member (10) and having at least one grip (74, 75, 76) that extends into said at least one groove (60, 62) so as to mount the saddle (70) on the body member (10) moveable in said longitudinal direction; and a means for maneuvering said body member (10).


Patent
King Faisal Specialist Hospital And Research Center | Date: 2015-01-14

A coupling assembly for securing an end of a tube to a connecting shaft of a device is provided. The coupling assembly comprises an inner sleeve having a first end, an opposite second end, a first end section at the first end and a second end section at the second end, and an outer sleeve having a first end, an opposite second end and a second end section at the second end. The second end section of the outer sleeve is sized and shaped to receive at least the first end section of the inner sleeve therein. An interior surface of the second end section of the outer sleeve is provided with a protrusion or a recess to engage a corresponding recess or protrusion on an exterior surface of the inner sleeve. The second end section of the inner sleeve is flexible.


Patent
King Saud University and King Faisal Specialist Hospital And Research Center | Date: 2016-03-16

The present invention relates to benzo-thiazolo-imidazole compounds and their uses. Moreover, the present invention relates to pharmaceutical compositions comprising such a benzo-thiazolo-imidazole compound. Furthermore, the present invention relates to the use of such a benzo-thiazolo-imidazole compound for the manipulation of cultured cells.


Patent
King Faisal Specialist Hospital And Research Center | Date: 2016-04-03

A spinal fixation device is provided, comprising a body member having a first side and an opposite second side, and an elongate flexible strap having a first section and a second section. The first section of the strap is attached or attachable to attachment means of the body member arranged at a first location thereof. The second section of the strap is sized and shaped to pass through a passageway arranged at a second location of the body member. The strap has a series of teeth and the passageway of the body member has a latch configured for engaging one of the teeth. The teeth and the latch are configured to allow a movement of the second section of the strap through the passageway in a tightening direction from the first side to the second side of the body member, and to prevent a movement of the second section in the opposite direction.


Patent
King Abdulaziz City for Science, Technology and King Faisal Specialist Hospital And Research Center | Date: 2015-01-28

The invention relates to a polymerizable composition including the monomer N-(isobutoxymethyl)acrylamide (NIBMA), a method of making it, a method of its use for planning a radiation treatment, and a 3D gel dosimeter comprising the composition. The polymerizable composition comprises: 2-5 w/w% of gelatin; 1-2 w/w% of N-(isobutoxymethyl)acrylamide (NIBMA); 1-4 w/w% of N,N-methylene-bis-acrylamide (BIS); optionally 1-20 mM of trakis(hydroxymethyl)phosphonium chloride (THPC); 0-29 w/w% of at least one co-solvent selected from the group consisting of glycerol, acetone and methanol; and ultra-pure de-ionized water as a solvent. Polymer gel dosimeters based on radiation-induced polymerization of N-(Isobutoxymethyl) acrylamide (NIBMA) polymer gels in normal atmospheric condition (NIBMAGAT) have been synthesized and studied as a new composition of polymer gel dosimeters for radiotherapy treatment planning. The dosimeters were irradiated with absorbed doses up to 30 Gy and no change in dose response was observed even after using repeatedly for eight times. The novel composition shows no change in the relaxation rate or absorbance of the gel dosimeters up to 144 hours. Dose response of NIBMAGAT gel dosimeters increases with increase of monomer concentration. The relaxation rate of NIBMAGAT gel increases with increase of THPC concentration from 2.5 to 5 mM, but the dose response is not affected with increase of THPC concentration from 5 to 20 mM. The results show that the dose sensitivity increases significantly with increase of glycerol concentration up to 30 % within gel dosimeters.


The present invention relates to benzo-thiazolo-imidazole compounds and their uses. Moreover, the present invention relates to pharmaceutical compositions comprising such a benzo-thiazolo-imidazole compound. Furthermore, the present invention relates to the use of such a benzo-thiazolo-imidazole compound for the manipulation of cultured cells.


Patent
King Faisal Specialist Hospital And Research Center | Date: 2014-03-19

The present invention relates to CD82 polypeptides of the mammalian tetraspanin CD82 protein family for use in the diagnosis, prevention and/or treatment of xenograft recognition and/or rejection. The present invention furthermore relates to CD82 knockout and transgenic animals and their cells, tissues and organs. The present invention furthermore relates to antibodies against a CD82 polypeptide, pharmaceutical compositions comprising at least one inhibitor of a CD82 polypeptide or comprising cells, tissues and organs of animals in which the CD82 level, expression and/or activity is modified, and their use in the diagnosis, prevention and/or treatment of xenograft recognition and/or rejection. The present invention furthermore relates to methods of diagnosing xenograft recognition and/or rejection and methods for the prevention and/or treatment of xenograft recognition and/or rejection as well as methods of xenotransplantation.


Patent
King Faisal Specialist Hospital And Research Center | Date: 2016-04-06

The present invention relates to CD82 polypeptides of the mammalian tetraspanin CD82 protein family for use in the diagnosis, prevention and/or treatment of xenograft recognition and/or rejection. The present invention furthermore relates to CD82 knockout and transgenic animals and their cells, tissues and organs. The present invention furthermore relates to antibodies against a CD82 polypeptide, pharmaceutical compositions comprising at least one inhibitor of a CD82 polypeptide or comprising cells, tissues and organs of animals in which the CD82 level, expression and/or activity is modified, and their use in the diagnosis, prevention and/or treatment of xenograft recognition and/or rejection. The present invention furthermore relates to methods of diagnosing xenograft recognition and/or rejection and methods for the prevention and/or treatment of xenograft recognition and/or rejection as well as methods of xenotransplantation.

Loading King Faisal Specialist Hospital And Research Center collaborators
Loading King Faisal Specialist Hospital And Research Center collaborators